WATERTOWN, Mass., March 16, 2023 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer, today announced the publication of abstracts for upcoming poster presentations at the American Association for Cancer Research (AACR) Annual Meeting 2023, taking place April 14-19 in Orlando, Florida.
Details for the abstract and poster presentation are as follows:
Title: Generation of IL-21 INDUKINE™ molecules for the treatment of cancer
Session Category: Immunology
Session Title: Immunomodulatory Agents and Interventions 2
Session Date and Time: Monday, April 17, 2023 from 9:00 a.m. - 12:30 p.m.
Location: Poster Section 24
Poster Board Number: 1
Title: Trial in progress: a multicenter phase 1/1b dose escalation study of WTX-124 as a monotherapy and in combination with pembrolizumab in patients with selected advanced or metastatic solid tumors
Session Title: Phase I Clinical Trials in Progress
Session Date and Time: Monday, April 17, 2023 from 1:30 p.m. - 5:00 p.m.
Location: Poster Section 46
Poster Board Number: 21
Abstract Presentation Number: CT254
Title: Trial in progress: a first-in-human, phase 1, multicenter dose escalation and dose expansion study of WTX-330 in adult patients with advanced or metastatic solid tumors or non-Hodgkin lymphoma
Session Title: Phase I and First-in-Human Clinical Trials in Progress
Session Date and Time: Tuesday, April 18, 2023 from 1:30 p.m. - 5:00 p.m.
Location: Poster Section 46
Poster Board Number: 17
About Werewolf Therapeutics
Werewolf Therapeutics, Inc., is an innovative biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer. We are leveraging our proprietary PREDATOR™ platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Our INDUKINE™ molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment. Our most advanced clinical stage product candidates, WTX-124 and WTX-330, are systemically delivered, conditionally activated Interleukin-2 (IL-2), and Interleukin-12 (IL-12) INDUKINE molecules, respectively, for the treatment of solid tumors. We expect to advance WTX-124 in multiple tumor types as a single agent and in combination with an immune checkpoint inhibitor and WTX-330 in multiple tumor types or Non-Hodgkin Lymphoma as a single agent. To learn more visit www.werewolftx.com.
Investor Contact:
Josh Rappaport
Stern IR
212.362.1200
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media Contact:
Peg Rusconi
VERGE Scientific Communications
This email address is being protected from spambots. You need JavaScript enabled to view it.
Company Contact:
Ellen Lubman
Chief Business Officer
Werewolf Therapeutics
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$6.24 |
| Daily Change: | -0.42 -6.31 |
| Daily Volume: | 143,134 |
| Market Cap: | US$270.500M |
March 07, 2024 | |
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MORE
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MORE
